Lumy Biosciences Secures Nearly RMB 100 Million in Pre-A Funding to Advance Its Next-Generation Light-Driven Carbon-Negative Biomanufacturing Platform

VCBeat has learned that Shanghai GuangYue Biotechnology Co., Ltd. (“GuangYue Bio”) recently announced the completion of its Pre-A financing round, raising nearly RMB 100 million.

This round of financing was invested by Oasis Capital. The proceeds will be used to advance and lay out the company’s new generation product pipeline, construct a carbon-negative synthesis base, and develop its talent team. Previously, GuangYue Biotechnology secured tens of millions of RMB in angel-round investment from Inno Angel Fund.

Lumy Biosciences, established in 2021, is dedicated toLight-Driven CO2 Recyclingan innovative synthetic biology company. GuangYue Biotechnology utilizes photosynthetic autotrophic cyanobacteria as a chassis, employing rational design and multi-dimensional editing for metabolic remodeling to construct nearly one hundred “carbon-negative” cell factories. This enables the direct use of solar energy and carbon dioxide for the targeted synthesis of various platform chemicals and natural products.

Synthetic biology engineers various chassis microorganisms, such as Escherichia coli and yeast, to produce a wide range of chemicals. As an alternative to traditional chemical engineering, this technology is applied across multiple sectors, including food, chemical industry, pharmaceuticals, and materials. However, most current synthetic biology technologies rely on chassis organisms that ferment sugars, resulting in high raw material costs and inevitable greenhouse gas emissions during production. In contrast, GuangYue Biotechnology has developed light-driven synthetic biology technology.，“Creating Compounds from Air, Reshaping the World with Recycled Carbon”, helping the biomanufacturing industry transition from carbon reduction to negative carbon emissions, thereby achieving genuine carbon sequestration.

GuangYue Biotechnology’s core R&D team has accumulated over a decade of technical expertise in photosynthetic biological engineering, the development of artificial photosynthetic microbial consortia, and metabolic modeling, resulting in numerous patented technologies in the field of light-driven synthetic biology. The core competency of a synthetic biology R&D company lies in the efficient iterative capability of its technology platform. GuangYue has developed novel foundational synthetic biology technologies, including the DTL-B metabolic optimization platform based on cofactor self-recycling cell-free systems, the DeepMARS pathway hyper-optimization system, and a flexible engineering framework for photosynthetic electron transport chains and carbon fixation. These innovations enable rapid strain development and enhanced synthetic performance.

Based on its proprietary technology platform, GuangYue Biotechnology has builtThe World's Leading Photosynthetic Cell Factory Library, enabling the targeted manufacturing of pharmaceutical ingredients, chemical raw materials, and biodegradable materials using carbon dioxide, thereby achieving a significant reduction in costs. Currently, GuangYue’s key focus areas areFunctional Active Ingredients, Health Nutrition, and Sustainable Agriculture, has achieved an ecological closed loop for the light-driven synthetic biology platform from R&D to application, and establishedMultiple business pipelines, including sakuranetin, ergothioneine, and bisdemethoxycurcumin。GuangYue Biotechnology, with its unique"Negative Carbon Production Model"To align closely with the national “Dual Carbon” policy and future manufacturing trends, we have signed commercial cooperation agreements with multiple leading enterprises in the industry. We expect to collaborate with industry leaders in the coming years to launch a variety of products, advancingInorganic Raw Materials, Reduced Carbon FootprintShao Hui, founder of GuangYue Biotechnology, stated, “GuangYue Biotechnology will continue to dedicate itself to the biological capture and high-value utilization of carbon, reshaping the world with recycled carbon to create a more sustainable future.”

Oasis Capital has long focused on investment opportunities in the field of synthetic biology. Oasis Capital believes that GuangYue Biotechnology, as a leader in next-generation carbon-negative synthetic biology technologies, has achieved the efficient conversion of CO2 into target products using light energy through means such as rational design, multi-dimensional editing, and electron chain remodeling. The company has developed various “Artificial Intelligence x Metabolic Rewiring” technologies based on its self-built computing platform, such as the pathway hyper-optimization system DeepMARS, which utilizes AI to optimize the spatial structure of multi-enzyme systems, precisely guide the assembly of molecular machines, and rapidly enhance the efficiency of synthetic pathways.

“The R&D team led by Professor Ni has mastered many of the most advanced core technologies in the field of light-driven synthetic biology, endowing its innovative technologies with significant application prospects. Carbon-negative biomanufacturing is a new generation of production methods that deliver both social and economic benefits. Oasis Capital is honored to partner with Professor Ni’s team and support their exploration and breakthroughs in light-driven synthetic biotechnology,” said a representative from Oasis Capital.

Oasis Capital is a new-generation venture capital firm in China, dedicated to identifying the most vital entrepreneurs of the next decade and growing alongside them to create long-term value. “Advising for Vitality” is Oasis’s vision and mission. This vitality represents both the direction of structural change in our era and the resilience and evolutionary power of entrepreneurs.

Oasis Capital focuses on early-stage and growth-stage investments, with individual investments ranging from $3 million to $30 million. It primarily invests in robotics, artificial intelligence, technology services, and other sectors, supporting the upgrade of new, technology-driven services in China.